Meiping Wang1, Wenjuan Chen1, Yu Geng1, Chenghua Xu2, Xiaoxiao Tao2, Yi Zhang2. 1. Department of Neurology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical. 2. Department of Neurology, Taizhou First People's Hospital, Huangyan Hospital of Wenzhou Medical University.
Abstract
AIM: This study focused on the expression pattern of long non-coding RNA maternally expressed gene 3 (MEG3) and its value in ischemic stroke (IS). METHODS: The expression pattern and the roles of MEG3 in the development of IS were explored in mice IS model and human brain microvascular endothelial cells (hBMECs). A case-control study, including 215 IS patients and 153 controls, was also conducted to investigate its prognostic value. RESULTS: In vivo study showed that MEG3 increased significantly in the IS group (P=0.004), and its level remained stable within 3 to 48h after the onset of IS. Besides, the survival time of the mouse in the high MEG3 group was significantly lower than that in the low MEG3 group (P=0.042). In vitro study showed that oxygen-glucose deprivation (OGD) treatment significantly up-regulated expressions of MEG3, Bax, and cleaved caspase-3, and further promoted apoptosis of hBMECs, while si-MEG3 blocked these effects. A human study showed that MEG3 increased markedly within 48h of IS onset and was positively associated with the National Institutes of Health Stroke Scale (r=0.347, P＜0.001), modified Rankin Scale (r=0.385, P＜0.001), high-sensitivity C-reactive protein (r=0.221, P=0.002) level, and infarct volume (r=0.201, P=0.006). Overall survival analysis showed that patients with higher MEG3 expression within 48h had a relatively poor prognosis (P＜0.001). Meanwhile, multivariate analysis revealed that MEG3 was an independent prognostic marker for unfavorable functional outcome and death in IS patients. CONCLUSIONS: This study suggested that MEG3 might be considered as an intervention point and potential prognostic indicator for IS.
AIM: This study focused on the expression pattern of long non-coding RNA maternally expressed gene 3 (MEG3) and its value in ischemic stroke (IS). METHODS: The expression pattern and the roles of MEG3 in the development of IS were explored in miceIS model and human brain microvascular endothelial cells (hBMECs). A case-control study, including 215 ISpatients and 153 controls, was also conducted to investigate its prognostic value. RESULTS: In vivo study showed that MEG3 increased significantly in the IS group (P=0.004), and its level remained stable within 3 to 48h after the onset of IS. Besides, the survival time of the mouse in the high MEG3 group was significantly lower than that in the low MEG3 group (P=0.042). In vitro study showed that oxygen-glucose deprivation (OGD) treatment significantly up-regulated expressions of MEG3, Bax, and cleaved caspase-3, and further promoted apoptosis of hBMECs, while si-MEG3 blocked these effects. A human study showed that MEG3 increased markedly within 48h of IS onset and was positively associated with the National Institutes of Health Stroke Scale (r=0.347, P＜0.001), modified Rankin Scale (r=0.385, P＜0.001), high-sensitivity C-reactive protein (r=0.221, P=0.002) level, and infarct volume (r=0.201, P=0.006). Overall survival analysis showed that patients with higher MEG3 expression within 48h had a relatively poor prognosis (P＜0.001). Meanwhile, multivariate analysis revealed that MEG3 was an independent prognostic marker for unfavorable functional outcome and death in ISpatients. CONCLUSIONS: This study suggested that MEG3 might be considered as an intervention point and potential prognostic indicator for IS.
Authors: Leo Kurian; Aitor Aguirre; Ignacio Sancho-Martinez; Christopher Benner; Tomoaki Hishida; Thai B Nguyen; Pradeep Reddy; Emmanuel Nivet; Marie N Krause; David A Nelles; Concepcion Rodriguez Esteban; Josep M Campistol; Gene W Yeo; Juan Carlos Izpisua Belmonte Journal: Circulation Date: 2015-03-04 Impact factor: 29.690
Authors: T Brott; J R Marler; C P Olinger; H P Adams; T Tomsick; W G Barsan; J Biller; R Eberle; V Hertzberg; M Walker Journal: Stroke Date: 1989-07 Impact factor: 7.914
Authors: Anna Motterle; Xiangyuan Pu; Harriet Wood; Qingzhong Xiao; Shivani Gor; Fu Liang Ng; Kenneth Chan; Frank Cross; Beski Shohreh; Robin N Poston; Arthur T Tucker; Mark J Caulfield; Shu Ye Journal: Hum Mol Genet Date: 2012-06-15 Impact factor: 6.150
Authors: Joanna M Wardlaw; Veronica Murray; Eivind Berge; Gregory del Zoppo; Peter Sandercock; Richard L Lindley; Geoff Cohen Journal: Lancet Date: 2012-05-23 Impact factor: 79.321